Argus Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Key Points

• Argus raised Merck’s price target from $145 to $170 and maintained a “buy” rating, implying 12.83% upside from the prior close.
• Analyst sentiment remains favorable: 15 analysts rate the stock a Buy and eight rate it a Hold, producing an overall “Moderate Buy” consensus and an average target of $145.35.
• Merck exceeded quarterly earnings and revenue expectations, while insiders sold 228,238 shares worth nearly $30 million over the last quarter; institutional investors own 76.07% of the company.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price target lifted by research analysts at Argus from $145.00 to $170.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Argus' target price would indicate a potential upside of 12.83% from the stock's previous close.

Several other brokerages have also recently weighed in on MRK. Barclays upped their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Scotiabank upped their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, June 30th. Finally, CICC Research assumed coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price on the stock. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $145.35.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $150.67 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $371.73 billion, a price-to-earnings ratio of 120.54, a PEG ratio of 6.40 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $154.49. The firm's 50-day moving average is $128.81 and its 200 day moving average is $121.53.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares of the company's stock, valued at approximately $6,106,303. The trade was a 24.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Richard R. Deluca sold 20,784 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company's stock.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently modified their holdings of the company. Round Rock Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 0.7% during the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock worth $1,272,000 after purchasing an additional 66 shares during the last quarter. Cascade Financial Partners LLC grew its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock worth $1,895,000 after purchasing an additional 80 shares during the period. Somerset Trust Co grew its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company's stock worth $1,118,000 after purchasing an additional 81 shares during the period. Stonebridge Financial Group LLC raised its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after buying an additional 81 shares during the last quarter. Finally, Stronghold Wealth Management L.L.C. lifted its holdings in shares of Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock valued at $416,000 after buying an additional 82 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source